Prabhavathi  Fernandes net worth and biography

Prabhavathi Fernandes Biography and Net Worth

Director of Ocugen
Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes is the Chairperson of both the National Biodefense Science Board (NBSB) and the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership, a DNDi/WHO initiative. She has also served as an advisor to the World Health Organization. She currently serves on the Boards of OpGen and Aelin Therapeutics. She has authored over 250 publications and several reviews, book chapters and served as an editor for books. Dr. Fernandes obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia.

What is Prabhavathi Fernandes' net worth?

The estimated net worth of Prabhavathi Fernandes is at least $29,737.50 as of May 25th, 2021. Dr. Fernandes owns 19,500 shares of Ocugen stock worth more than $29,738 as of April 16th. This net worth estimate does not reflect any other investments that Dr. Fernandes may own. Learn More about Prabhavathi Fernandes' net worth.

How do I contact Prabhavathi Fernandes?

The corporate mailing address for Dr. Fernandes and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Prabhavathi Fernandes' contact information.

Has Prabhavathi Fernandes been buying or selling shares of Ocugen?

Prabhavathi Fernandes has not been actively trading shares of Ocugen within the last three months. Most recently, Prabhavathi Fernandes sold 33,500 shares of the business's stock in a transaction on Tuesday, May 25th. The shares were sold at an average price of $8.20, for a transaction totalling $274,700.00. Following the completion of the sale, the director now directly owns 19,500 shares of the company's stock, valued at $159,900. Learn More on Prabhavathi Fernandes' trading history.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Are insiders buying or selling shares of Ocugen?

In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.

Information on this page was last updated on 6/14/2023.

Prabhavathi Fernandes Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2021Sell33,500$8.20$274,700.0019,500View SEC Filing Icon  
See Full Table

Prabhavathi Fernandes Buying and Selling Activity at Ocugen

This chart shows Prabhavathi Fernandes's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.59
Low: $1.52
High: $1.60

50 Day Range

MA: $1.16
Low: $0.52
High: $1.88

2 Week Range

Now: $1.59
Low: $0.35
High: $2.11


2,980,150 shs

Average Volume

8,161,378 shs

Market Capitalization

$407.84 million

P/E Ratio


Dividend Yield